These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 35853842

  • 21. The β-Adrenergic Agonist Albuterol Improves Pulmonary Vascular Reserve in Heart Failure With Preserved Ejection Fraction.
    Reddy YNV, Obokata M, Koepp KE, Egbe AC, Wiley B, Borlaug BA.
    Circ Res; 2019 Jan 18; 124(2):306-314. PubMed ID: 30582447
    [Abstract] [Full Text] [Related]

  • 22. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study.
    Lindman BR, Dávila-Román VG, Mann DL, McNulty S, Semigran MJ, Lewis GD, de las Fuentes L, Joseph SM, Vader J, Hernandez AF, Redfield MM.
    J Am Coll Cardiol; 2014 Aug 12; 64(6):541-9. PubMed ID: 25104521
    [Abstract] [Full Text] [Related]

  • 23. Effect of sildenafil on cardiac performance in patients with heart failure.
    Hirata K, Adji A, Vlachopoulos C, O'Rourke MF.
    Am J Cardiol; 2005 Nov 15; 96(10):1436-40. PubMed ID: 16275194
    [Abstract] [Full Text] [Related]

  • 24. Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction.
    Udelson JE, DeAbate CA, Berk M, Neuberg G, Packer M, Vijay NK, Gorwitt J, Smith WB, Kukin ML, LeJemtel T, Levine TB, Konstam MA.
    Am Heart J; 2000 Mar 15; 139(3):503-10. PubMed ID: 10689266
    [Abstract] [Full Text] [Related]

  • 25. The immediate effect of sildenafil on right ventricular function in patients with heart failure measured by cardiac magnetic resonance: a randomized control trial.
    Fernandes AM, Andrade AC, Barroso ND, Borges IC, Carvalho-Andrade D, Rodrigues Junior ES, Guimarães LC, Durães AR, Borges SM, Aras Junior R.
    PLoS One; 2015 Mar 15; 10(3):e0119623. PubMed ID: 25793988
    [Abstract] [Full Text] [Related]

  • 26. Development of a Human Model for the Study of Effects of Hypoxia, Exercise, and Sildenafil on Cardiac and Vascular Function in Chronic Heart Failure.
    Damy T, Hobkirk J, Walters M, Ciobanu A, Rigby AS, Kallvikbacka-Bennett A, Guellich A, Dubois-Randé JL, Hittinger L, Clark AL, Cleland JG.
    J Cardiovasc Pharmacol; 2015 Sep 15; 66(3):229-38. PubMed ID: 25874853
    [Abstract] [Full Text] [Related]

  • 27. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial.
    Bermejo J, Yotti R, García-Orta R, Sánchez-Fernández PL, Castaño M, Segovia-Cubero J, Escribano-Subías P, San Román JA, Borrás X, Alonso-Gómez A, Botas J, Crespo-Leiro MG, Velasco S, Bayés-Genís A, López A, Muñoz-Aguilera R, de Teresa E, González-Juanatey JR, Evangelista A, Mombiela T, González-Mansilla A, Elízaga J, Martín-Moreiras J, González-Santos JM, Moreno-Escobar E, Fernández-Avilés F, Sildenafil for Improving Outcomes after VAlvular Correction (SIOVAC) investigators.
    Eur Heart J; 2018 Apr 14; 39(15):1255-1264. PubMed ID: 29281101
    [Abstract] [Full Text] [Related]

  • 28. Pulmonary vascular and right ventricular reserve in patients with normalized resting hemodynamics after pulmonary endarterectomy.
    Claessen G, La Gerche A, Dymarkowski S, Claus P, Delcroix M, Heidbuchel H.
    J Am Heart Assoc; 2015 Mar 23; 4(3):e001602. PubMed ID: 25801760
    [Abstract] [Full Text] [Related]

  • 29. Moving beyond the vasodilator model in heart failure with reduced ejection fraction - lessons from sildenafil.
    Reddy YNV.
    Eur J Heart Fail; 2022 Jul 23; 24(7):1249-1252. PubMed ID: 35717600
    [No Abstract] [Full Text] [Related]

  • 30. Pulmonary Hypertension secondary to Left Heart Disease.
    Kabbach G, Mukherjee D.
    Curr Vasc Pharmacol; 2018 Jul 23; 16(6):555-560. PubMed ID: 28901848
    [Abstract] [Full Text] [Related]

  • 31. Cardiac correlates of exercise induced pulmonary hypertension in patients with chronic heart failure due to left ventricular systolic dysfunction.
    Maréchaux S, Pinçon C, Le Tourneau T, de Groote P, Huerre C, Asseman P, Van Belle E, Nevière R, Bauters C, Deklunder G, Lejemtel TH, Ennezat PV.
    Echocardiography; 2008 Apr 23; 25(4):386-93. PubMed ID: 18177381
    [Abstract] [Full Text] [Related]

  • 32. PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; A 12-week, randomized, double-blind, placebo-controlled trial.
    Kim KH, Kim HK, Hwang IC, Cho HJ, Je N, Kwon OM, Choi SJ, Lee SP, Kim YJ, Sohn DW.
    Am Heart J; 2015 Jun 23; 169(6):813-822.e3. PubMed ID: 26027619
    [Abstract] [Full Text] [Related]

  • 33. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction.
    Bocchi EA, Guimarães G, Mocelin A, Bacal F, Bellotti G, Ramires JF.
    Circulation; 2002 Aug 27; 106(9):1097-103. PubMed ID: 12196335
    [Abstract] [Full Text] [Related]

  • 34. CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction.
    de Denus S, Rouleau JL, Mann DL, Huggins GS, Pereira NL, Shah SH, Cappola TP, Fouodjio R, Mongrain I, Dubé MP.
    Pharmacogenomics J; 2018 Apr 27; 18(2):232-237. PubMed ID: 28440343
    [Abstract] [Full Text] [Related]

  • 35. Chronic Sildenafil Therapy in the ZSF1 Obese Rat Model of Metabolic Syndrome and Heart Failure With Preserved Ejection Fraction.
    Leite S, Moreira-Costa L, Cerqueira R, Sousa-Mendes C, Angélico-Gonçalves A, Fontoura D, Vasques-Nóvoa F, Leite-Moreira AF, Lourenço AP.
    J Cardiovasc Pharmacol Ther; 2021 Nov 27; 26(6):690-701. PubMed ID: 34328815
    [Abstract] [Full Text] [Related]

  • 36. Management of combined pre- and post-capillary pulmonary hypertension in advanced heart failure with reduced ejection fraction.
    Sahay S, Khirfan G, Tonelli AR.
    Respir Med; 2017 Oct 27; 131():94-100. PubMed ID: 28947049
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design.
    Behr J, Nathan SD, Harari S, Wuyts W, Kirchgaessler KU, Bengus M, Gilberg F, Wells AU.
    Respir Med; 2018 May 27; 138():13-20. PubMed ID: 29724385
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.